Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

RedHill Biopharma (RDHL) EBT Margin: 2012-2023

Historic EBT Margin for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to 3,280.68%.

  • RedHill Biopharma's EBT Margin rose 352580.00% to 3,280.68% in Q2 2023 from the same period last year, while for Jun 2023 it was -111.91%, marking a year-over-year increase of 10647.00%. This contributed to the annual value of -102.80% for FY2024, which is 46905.00% down from last year.
  • Latest data reveals that RedHill Biopharma reported EBT Margin of 3,280.68% as of Q2 2023, which was up 1,590.99% from -220.03% recorded in Q1 2023.
  • In the past 5 years, RedHill Biopharma's EBT Margin registered a high of 3,280.68% during Q2 2023, and its lowest value of -658.08% during Q4 2021.
  • Moreover, its 3-year median value for EBT Margin was -30.18% (2021), whereas its average is 181.24%.
  • In the last 5 years, RedHill Biopharma's EBT Margin plummeted by 149,215bps in 2021 and then skyrocketed by 352,580bps in 2023.
  • RedHill Biopharma's EBT Margin (Quarterly) stood at 744.47% in 2019, then slumped by 65,273bps to 91.74% in 2020, then slumped by 74,982bps to -658.08% in 2021, then surged by 11,486bps to -543.22% in 2022, then surged by 352,580bps to 3,280.68% in 2023.
  • Its EBT Margin stands at 3,280.68% for Q2 2023, versus -220.03% for Q1 2023 and -543.22% for Q4 2022.